Cancer Immunotherapy Stocks List

Cancer Immunotherapy Stocks Recent News

Date Stock Title
May 12 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 10 RCUS Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
May 10 TIL Instil Bio reports Q1 results
May 10 RCUS Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
May 10 SNTI Senti Biosciences GAAP EPS of -$0.26
May 10 TIL Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9 PDSB PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
May 9 SNTI Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 9 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
May 9 SNSE Sensei Biotherapeutics GAAP EPS of -$0.32
May 9 PDSB PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
May 9 SNSE Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 9 RCUS Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 9 RCUS Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
May 8 RCUS Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
May 8 RCUS Arcus Biosciences GAAP EPS of -$0.05 beats by $0.92, revenue of $145M beats by $116.23M
May 8 RCUS Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
May 7 RCUS Arcus Biosciences Q1 2024 Earnings Preview
May 7 PDSB PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
May 6 TCBP TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
Cancer Immunotherapy

Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system's natural ability to fight cancer. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules (e.g. carbohydrates). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill.

Browse All Tags